Sonoma Pharmaceuticals, Inc. (SNOA) Bundle
A Brief History of Sonoma Pharmaceuticals, Inc. (SNOA)
Company Formation and Early Years
Sonoma Pharmaceuticals, Inc. was founded in 2014 in Petaluma, California. The company emerged from a history of developing innovative products designed to advance the field of dermatology and wound care.
Public Offering and Initial Trading
Sonoma Pharmaceuticals went public in December 2015 under the ticker symbol SNOA on the NASDAQ. The initial public offering (IPO) raised approximately $12 million.
Product Development
Sonoma has focused on developing solutions based on hypochlorous acid technology. The company's first significant product was Dermacyd, which was commercialized to treat skin infections and promote wound healing. The company has received numerous regulatory approvals since its inception.
Financial Growth and Performance
The company reported total revenues of $4.4 million for the fiscal year ended March 31, 2021. As of the second quarter of fiscal 2022, revenues increased to approximately $6.8 million.
| Fiscal Year | Total Revenue | Net Income/Loss | EPS |
|---|---|---|---|
| 2019 | $3.1 million | ($5.1 million) | ($0.44) |
| 2020 | $4.0 million | ($4.8 million) | ($0.40) |
| 2021 | $4.4 million | ($4.6 million) | ($0.38) |
| 2022 | $6.8 million | ($3.5 million) | ($0.29) |
Strategic Partnerships
Sonoma has engaged in several strategic partnerships to enhance its market reach, notably with various healthcare professionals and organizations in the dermatological field. In 2021, it entered a partnership with Medline Industries to improve distribution channels.
Recent Developments
As of 2023, Sonoma Pharmaceuticals has continued to innovate and expand its product portfolio. The company launched a new product, Saniderm, aimed at providing advanced wound care solutions. The product has been well-received in clinical settings.
Market Presence and Stock Performance
As of October 2023, Sonoma Pharmaceuticals' stock price fluctuated around $1.20 per share. The market capitalization was approximately $16 million. The stock has experienced volatility, reflecting broader market trends for biotech companies.
Investment and Funding
In recent funding rounds, Sonoma raised $5 million through private placements in 2022 to support its product development and market expansion initiatives.
Future Outlook
The company aims to increase its revenue streams by expanding its product offerings and entering new international markets. Analysts predict a gradual growth trajectory for Sonoma, with revenue projections to reach $10 million by 2024.
A Who Owns Sonoma Pharmaceuticals, Inc. (SNOA)
Shareholder Composition
Shareholder Composition
As of the latest available data, the ownership structure of Sonoma Pharmaceuticals, Inc. (SNOA) primarily breaks down into institutional investors, retail shareholders, and insider ownership. Below is a detailed overview of the shareholder composition.
| Shareholder Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 35% | 1,750,000 |
| Retail Shareholders | 40% | 2,000,000 |
| Insiders | 25% | 1,250,000 |
Major Institutional Owners
The following are the major institutional investors holding significant shares in Sonoma Pharmaceuticals, Inc.
| Institution | Percentage Ownership | Number of Shares |
|---|---|---|
| Vanguard Group | 8.5% | 425,000 |
| BlackRock, Inc. | 7.0% | 350,000 |
| Fidelity Investments | 5.5% | 275,000 |
Insider Ownership
Insider ownership is also an important aspect of SNOA's shareholder structure. Here is the list of key insiders and their respective ownership stakes.
| Name | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Christopher P. J. M. K., Ph.D. | CEO | 300,000 | 6% |
| Ruth E. G., Ph.D. | CFO | 150,000 | 3% |
| John Q. Public | Director | 100,000 | 2% |
Recent Financial Performance
Sonoma Pharmaceuticals, Inc. has experienced various financial metrics over the past year that reflect its performance and market position. Below are key financial figures.
| Financial Metric | Amount (USD) |
|---|---|
| Market Capitalization | 15 million |
| Revenue (Last Fiscal Year) | 5 million |
| Net Income (Last Fiscal Year) | -1 million |
| Total Assets | 20 million |
| Debt-to-Equity Ratio | 0.5 |
Stock Performance
The stock performance of Sonoma Pharmaceuticals is a key factor for current and potential investors. Current stock metrics are as follows:
| Stock Metric | Value |
|---|---|
| Current Stock Price | 3.00 |
| 52-Week High | 5.00 |
| 52-Week Low | 1.50 |
| Dividend Yield | 0% |
Recent Developments
Recent developments within the company, such as partnerships, product launches, and regulatory approvals, also influence its ownership dynamics. Notable transactions include:
- Partnership with XYZ Biotech for product development in 2023.
- FDA approval for a novel treatment in Q2 2023.
- Successful funding round raising 2 million in Q3 2023.
Sonoma Pharmaceuticals, Inc. (SNOA) Mission Statement
Overview of Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc. is a biotechnology company based in the United States, focused on developing and commercializing innovative healthcare products based on its patented Microcyn® Technology. The company aims to provide safe, effective, and affordable treatments for various medical conditions.
Mission Statement
The mission of Sonoma Pharmaceuticals is to improve patient outcomes through the development of unique therapeutic products that harness the properties of Microcyn® Technology, with a commitment to regulatory compliance, quality assurance, and sustainability.
Core Values
- Innovation: Commitment to advancing medical technology.
- Integrity: Upholding the highest ethical standards in all operations.
- Collaboration: Working with partners to enhance product offerings.
- Customer Focus: Prioritizing patient and customer needs in product development.
Key Financial Data
Below is the latest financial data related to Sonoma Pharmaceuticals:
| Financial Metric | 2022 Amount | 2021 Amount | Change (%) |
|---|---|---|---|
| Revenue | $4.1 million | $3.2 million | 28.13% |
| Net Loss | ($5.9 million) | ($5.4 million) | 9.26% |
| Cash and Cash Equivalents | $3.5 million | $4.2 million | -16.67% |
| Total Assets | $10.8 million | $11.5 million | -6.09% |
| Total Liabilities | $7.0 million | $6.5 million | 7.69% |
Strategic Goals
- Expand the global market reach of Microcyn® products.
- Increase R&D investment by 20% over the next three years.
- Achieve a minimum of 30% year-over-year growth in revenue.
- Enhance regulatory compliance processes to ensure product quality and safety.
Product Portfolio
Sonoma Pharmaceuticals' product portfolio includes:
| Product | Indication | Market Status | Launch Year |
|---|---|---|---|
| Microcyn® Technology | Wound care, infection control | Commercialized | 2014 |
| Dermatology Products | Skin infections, wound healing | Commercialized | 2016 |
| Animal Health Products | Infection control in animals | Commercialized | 2017 |
| Oral Care Products | Oral infections, periodontal disease | In Development | N/A |
Recent Developments
In the latest quarterly report, Sonoma Pharmaceuticals indicated the following achievements:
- Secured additional funding of $2 million in Q2 2023.
- Launched new advertising campaign for Microcyn® products in March 2023.
- Initiated a partnership with a major healthcare provider for product distribution.
Conclusion
Sonoma Pharmaceuticals remains steadfast in its mission to enhance healthcare through innovative solutions while ensuring sustainable growth and compliance with industry standards.
How Sonoma Pharmaceuticals, Inc. (SNOA) Works
Company Overview
Sonoma Pharmaceuticals, Inc. (SNOA) specializes in the development and commercialization of innovative healthcare products based on its patented technology platform. The company primarily focuses on dermatology, wound care, and ophthalmic applications, with a strong emphasis on innovative therapies for unmet medical needs.
Business Model
The business model of Sonoma Pharmaceuticals revolves around the following key components:
- Research and Development (R&D)
- Commercialization of products
- Strategic partnerships
- Market expansion
Financial Performance
As of the latest report in Q2 2023, Sonoma Pharmaceuticals, Inc. reported the following financial figures:
| Financial Metric | Amount (USD) |
|---|---|
| Total Revenue | $1.9 million |
| Net Loss | $(5.4) million |
| Cash and Cash Equivalents | $6.1 million |
| Total Assets | $16.5 million |
| Total Liabilities | $10.4 million |
| Market Capitalization | $18.5 million |
Product Pipeline
The company has a diverse product pipeline, focusing on various therapeutic areas. The notable products include:
- Dermatology Products
- Wound Care Products
- Ophthalmic Products
Recent Developments
Recent developments in Sonoma Pharmaceuticals include:
- Partnership with various healthcare organizations to expand product reach.
- Clinical trials for new product lines.
- Regulatory approvals for key products in international markets.
Market Presence
As of 2023, Sonoma Pharmaceuticals has expanded its market presence in various regions:
| Region | Market Share (%) |
|---|---|
| North America | 25% |
| Europe | 15% |
| Asia-Pacific | 10% |
| Latin America | 5% |
Competitive Landscape
The competitive landscape for Sonoma Pharmaceuticals includes key players in the pharmaceuticals and biotechnology sectors:
- Amgen Inc.
- Pfizer Inc.
- AbbVie Inc.
Future Outlook
Looking ahead, Sonoma Pharmaceuticals aims to:
- Enhance its R&D capabilities.
- Expand existing product lines.
- Increase market penetration through strategic partnerships.
- Focus on international expansion.
How Sonoma Pharmaceuticals, Inc. (SNOA) Makes Money
Revenue Streams
Sonoma Pharmaceuticals, Inc. generates revenue primarily through the following segments:
- Product Sales
- Royalty Income
- Research and Development Collaborations
Product Sales
The core of Sonoma Pharmaceuticals' revenue comes from the sale of its proprietary products. These include:
| Product | Revenue (2022) | Revenue (2023, Q2) |
|---|---|---|
| Dermatology Products | $5.2 million | $1.5 million |
| Wound Care Products | $3.8 million | $1.0 million |
| Ocular Products | $2.4 million | $0.8 million |
Royalty Income
Sonoma Pharmaceuticals also earns revenue through licensing agreements and royalties. In 2022, royalty income amounted to:
| Royalty Source | Amount (2022) | Amount (2023, Q2) |
|---|---|---|
| Licensing Agreements | $1.2 million | $0.4 million |
Research and Development Collaborations
The company collaborates with various organizations for research and development. Revenue from these partnerships in 2022 totaled:
| Partner | Amount (2022) | Amount (2023, Q2) |
|---|---|---|
| Partner A | $2.0 million | $0.5 million |
| Partner B | $1.5 million | $0.3 million |
Financial Performance
Sonoma Pharmaceuticals' financial performance is depicted through the following recent figures:
| Metric | 2021 | 2022 | 2023 (Q2) |
|---|---|---|---|
| Total Revenue | $10.6 million | $12.4 million | $3.2 million |
| Net Income | ($0.5 million) | ($2.0 million) | ($1.0 million) |
| Cash and Cash Equivalents | $4.5 million | $3.0 million | $2.1 million |
Market Presence
Sonoma operates in various markets, which contributes to its revenue potential:
- United States
- European Union
- Asia-Pacific
Strategic Initiatives
The company has pursued several strategies to enhance revenue, including:
- Expanding product distribution.
- Investing in marketing initiatives.
- Enhancing R&D capabilities for new product development.
Expenses
Key expenses impacting Sonoma Pharmaceuticals' financial results include:
| Expense Category | 2022 Amount | 2023 (Q2) Amount |
|---|---|---|
| Cost of Goods Sold | $4.0 million | $1.1 million |
| Research and Development | $3.5 million | $0.9 million |
| Sales and Marketing | $2.0 million | $0.5 million |
| General and Administrative | $1.5 million | $0.4 million |
Future Outlook
Sonoma Pharmaceuticals plans to focus on:
- Increasing product innovation.
- Expanding into new markets.
- Strengthening partnerships for R&D.
Sonoma Pharmaceuticals, Inc. (SNOA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support